PEDIATRICS Vol. 77 No. 4 April 1986, pp. 553-556
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by SINGER, H. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by SINGER, H. S.

Tardive Dyskinesia: A Concern for the Pediatrician

HARVEY S. SINGER MD1

1 Departments of Pediatrics and Neurology, The Johns Hopkins University School of Medicine, Baltimore

Antipsychotic drugs, such as the phenothiazines (chlorpromazine, fluphenazine, thioridazine), butyrophenones (haloperiodol), and diphenylbutylpiperidines (pimozide) are used in children and adolescents to treat a variety of clinical entities including psychoses, tics, behavior disorders, and movement problems. Because virtually all of these drugs have a potential to affect body movements and posture, they have also been termed neuroleptics.1 Most physicians are aware of the more common acute extrapyramidal side effects of these drugs, such as oculogyria, pseudoparkinsonism, dystonia, and restlessness (akathisia). Despite the widespread use of neuroleptics, however, little is known about the long-term neurologic consequences of such treatment. Of particular concern, based originally on data in adults, is the risk of severe and persistent tardive dyskinesia developing in persons receiving neuroleptic therapy.




This article has been cited by other articles:


Home page
 NeurologyHome page
D. L. Gilbert, G. Sethuraman, L. Sine, S. Peters, and F. R. Sallee
Tourette's syndrome improvement with pergolide in a randomized, double-blind, crossover trial
Neurology, March 28, 2000; 54(6): 1310 - 1315.
[Abstract] [Full Text] [PDF]